In this video, Andres Deik, MD, MSEd, FAAN, discusses the results of the CYCLE-II trial, presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders.

Degradation studies indicated that about 82% of the implants disintegrated within seven days. Complete degradation of the ...

The cell therapy field has long held a transformative ambition: to create "off-the-shelf" treatments that can reach not just ...

Smart implants and closed-loop systems are at the forefront of precision healthcare, enabling real-time diagnostics and ...

When should someone consider therapy services, and how do they know which type of therapy is best? That question is answered ...

A genetic analysis of blood samples reveals molecular changes in early-stage Parkinson’s patients, offering a non-invasive ...

Die Transkranielle Pulsstimulation (TPS) ist ein innovatives, nicht-invasives Verfahren der funktionellen Neuromodulation, ...

Bayer AG, in collaboration with BlueRock Therapeutics, is conducting a Phase 3 study titled ‘exPDite-2’ to evaluate the efficacy and safety of bemdaneprocel, a midbrain dopaminergic neuronal cell ...

The aggregate gross proceeds to the Company from the offering are expected to be approximately $3.4 million, before deducting the placement agent fees and other offering expenses payable by the ...

This FTSE 250 biotech pioneer has soared in price since April, but Simon Watkins believes spectacular earnings growth prospects could drive it much higher. The post Up 163%, what’s going on with this ...

NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class ...

New research suggests that psychedelic drugs may work by strengthening specific brain connections linked to memory and cognition.